X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs SANOFI INDIA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD SANOFI INDIA BIOCON LTD/
SANOFI INDIA
 
P/E (TTM) x 84.6 32.8 257.6% View Chart
P/BV x 8.0 6.3 127.3% View Chart
Dividend Yield % 0.2 1.4 10.8%  

Financials

 BIOCON LTD   SANOFI INDIA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
SANOFI INDIA
Dec-16
BIOCON LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1624,560 25.5%   
Low Rs4834,400 11.0%   
Sales per share (Unadj.) Rs194.61,028.5 18.9%  
Earnings per share (Unadj.) Rs34.4129.0 26.7%  
Cash flow per share (Unadj.) Rs48.3186.0 26.0%  
Dividends per share (Unadj.) Rs1.0068.00 1.5%  
Dividend yield (eoy) %0.11.5 8.0%  
Book value per share (Unadj.) Rs241.9753.6 32.1%  
Shares outstanding (eoy) m200.0023.03 868.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.4 97.0%   
Avg P/E ratio x23.934.7 68.8%  
P/CF ratio (eoy) x17.024.1 70.7%  
Price / Book Value ratio x3.45.9 57.2%  
Dividend payout %2.952.7 5.5%   
Avg Mkt Cap Rs m164,440103,174 159.4%   
No. of employees `0009.23.6 254.9%   
Total wages/salary Rs m7,4703,592 208.0%   
Avg. sales/employee Rs Th4,213.96,537.7 64.5%   
Avg. wages/employee Rs Th809.0991.4 81.6%   
Avg. net profit/employee Rs Th745.2819.8 90.9%   
INCOME DATA
Net Sales Rs m38,91123,686 164.3%  
Other income Rs m1,571708 221.9%   
Total revenues Rs m40,48224,394 166.0%   
Gross profit Rs m9,7955,281 185.5%  
Depreciation Rs m2,7721,313 211.1%   
Interest Rs m26015 1,733.3%   
Profit before tax Rs m8,3344,661 178.8%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6161,691 95.6%   
Profit after tax Rs m6,8812,970 231.7%  
Gross profit margin %25.222.3 112.9%  
Effective tax rate %19.436.3 53.4%   
Net profit margin %17.712.5 141.0%  
BALANCE SHEET DATA
Current assets Rs m40,47715,673 258.3%   
Current liabilities Rs m16,7836,678 251.3%   
Net working cap to sales %60.938.0 160.3%  
Current ratio x2.42.3 102.8%  
Inventory Days Days6076 78.4%  
Debtors Days Days8322 371.3%  
Net fixed assets Rs m45,0738,098 556.6%   
Share capital Rs m1,000230 434.2%   
"Free" reserves Rs m47,37717,088 277.3%   
Net worth Rs m48,37717,356 278.7%   
Long term debt Rs m21,0820-   
Total assets Rs m93,94225,400 369.9%  
Interest coverage x33.1311.7 10.6%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.40.9 44.4%   
Return on assets %7.611.8 64.7%  
Return on equity %14.217.1 83.1%  
Return on capital %12.626.9 46.8%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m12,9887,145 181.8%   
Fx outflow Rs m7,8996,846 115.4%   
Net fx Rs m5,089299 1,702.0%   
CASH FLOW
From Operations Rs m6,4003,226 198.4%  
From Investments Rs m-4,985-1,555 320.6%  
From Financial Activity Rs m-1,775-1,818 97.6%  
Net Cashflow Rs m-473-147 321.8%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS